PL377896A1 - Związki modulujące transport glutaminianu i sposoby modulowania transportu glutaminianu - Google Patents

Związki modulujące transport glutaminianu i sposoby modulowania transportu glutaminianu

Info

Publication number
PL377896A1
PL377896A1 PL377896A PL37789604A PL377896A1 PL 377896 A1 PL377896 A1 PL 377896A1 PL 377896 A PL377896 A PL 377896A PL 37789604 A PL37789604 A PL 37789604A PL 377896 A1 PL377896 A1 PL 377896A1
Authority
PL
Poland
Prior art keywords
methods
modulatory compounds
glutamate transport
protein expression
eaat
Prior art date
Application number
PL377896A
Other languages
English (en)
Inventor
Jeffrey D. Rothstein
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of PL377896A1 publication Critical patent/PL377896A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • General Engineering & Computer Science (AREA)
PL377896A 2003-02-26 2004-02-25 Związki modulujące transport glutaminianu i sposoby modulowania transportu glutaminianu PL377896A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45022703P 2003-02-26 2003-02-26

Publications (1)

Publication Number Publication Date
PL377896A1 true PL377896A1 (pl) 2006-02-20

Family

ID=32927622

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377896A PL377896A1 (pl) 2003-02-26 2004-02-25 Związki modulujące transport glutaminianu i sposoby modulowania transportu glutaminianu

Country Status (13)

Country Link
US (1) US20060121488A1 (pl)
EP (1) EP1611238B1 (pl)
JP (1) JP2006524637A (pl)
KR (1) KR20050115245A (pl)
AT (1) ATE433993T1 (pl)
AU (1) AU2004214938B2 (pl)
CA (1) CA2516619A1 (pl)
DE (1) DE602004021574D1 (pl)
DK (1) DK1611238T3 (pl)
ES (1) ES2328811T3 (pl)
MX (1) MXPA05009134A (pl)
PL (1) PL377896A1 (pl)
WO (1) WO2004076675A2 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050083971A (ko) 2002-11-22 2005-08-26 더 존스 홉킨스 유니버시티 인지능 손상의 치료를 위한 표적
AU2004285473A1 (en) * 2003-10-21 2005-05-12 Johns Hopkins University Neuroprotection with beta-lactam compounds
US20060205704A1 (en) * 2005-03-04 2006-09-14 Alsgen, Llc Modulation of neurodegenerative diseases through the progesterone receptor
EP1874353A1 (en) 2005-04-05 2008-01-09 Yale University Glutamate modulating agents in the treatment of mental disorders
EP1983988A2 (en) * 2006-02-16 2008-10-29 The McLean Hospital Corporation Methods and compositions for the treatment of parkinson's disease
FR2902010B1 (fr) * 2006-06-12 2008-08-22 Pierre Fabre Medicament Sa Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique
US20100248986A1 (en) * 2007-09-06 2010-09-30 Firestein-Miller Bonnie L Methods and kits for identification of anti-excitotoxic compounds
US20110201668A1 (en) * 2008-01-30 2011-08-18 Korea Institute Of Science And Technology Regulation of neurotransmitter release through anion channels
JP5850321B2 (ja) * 2010-02-10 2016-02-03 公立大学法人横浜市立大学 神経選択的転写抑制因子ＮＲＳＦに特異的に結合するｍＳｉｎ３Ｂに結合する化合物の利用
FR2958664B1 (fr) 2010-04-07 2012-10-26 Coatex Sas Utilisation d'un latex de styrene et de taille de 100 nm comme agent rheologique dans une sauce de couchage papetiere, sauce et son procede d'obtention
KR101351181B1 (ko) 2010-05-11 2014-01-14 가천대학교 산학협력단 단핵식세포계 세포 내에서 ａｇｅ-알부민의 합성 저해 또는 분비 저해에 의한 세포사 유도 저해 방법
US20130303562A1 (en) * 2010-12-02 2013-11-14 Massachusetts Institute Of Technology Chemical and rnai suppressors of neurotoxicity in huntington's disease
WO2014076702A1 (en) * 2012-11-14 2014-05-22 Ramot At Tel-Aviv University Ltd. Combination treatment for amyotrophic lateral sclerosis (als)
US10448861B2 (en) * 2013-09-06 2019-10-22 Covidien Lp System and method for light based lung visualization
CN104074095A (zh) * 2014-06-25 2014-10-01 宁波天源科技有限公司 流变改质剂
KR101809379B1 (ko) * 2016-10-13 2017-12-14 연세대학교 산학협력단 디오스민 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물
CN111116374B (zh) * 2019-12-04 2020-12-15 北京理工大学 一种氨鲁米特与2-硝基苯甲酸合成π-π键共晶体的方法
CN110923148B (zh) * 2019-12-11 2021-05-14 华北制药股份有限公司 青霉素v钾高产菌及其在发酵生产青霉素v钾中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575506A (en) * 1983-11-03 1986-03-11 Zambon S.P.A. Method of treatment for inhibiting the tolerance onset while treating painful syndromes with central analgesics
US5210076A (en) 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
ATE136461T1 (de) * 1990-08-13 1996-04-15 Searle & Co Verwendung von heterozyklischen aminoalkoholverbindungen zur herstellung eines medikaments für die behandlung von erkrankungen des zns
US5658782A (en) * 1993-10-20 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization Amino acid transporters and uses
US5795563A (en) * 1996-09-04 1998-08-18 Sphingomonas Research Partners, L.P. Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment
US6255467B1 (en) * 1997-11-06 2001-07-03 Pathobiotek Diagnostics Inc. Human blood bacterium
US7060457B2 (en) * 1998-03-18 2006-06-13 Johns Hopkins University Aberrant glutamate transporters and methods of use
ATE305921T1 (de) * 1998-05-15 2005-10-15 Univ Vermont Neue analoga von 16-hydroxyeicosatetraensäure
WO2001012184A1 (en) * 1999-08-16 2001-02-22 Revaax Pharmaceuticals, Llc Neurotherapeutic composition and method
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US6248360B1 (en) * 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
AU2001288792A1 (en) * 2000-09-06 2002-03-22 Neurotherapeutics, Llc Method of treating neurologic disorders
US6833478B2 (en) * 2001-07-13 2004-12-21 Sri International N,N-dinitramide salts as solubilizing agents for biologically active agents
WO2003070965A2 (en) * 2002-02-15 2003-08-28 The Johns Hopkins University The eaat2 promoter and uses thereof
KR20050083971A (ko) * 2002-11-22 2005-08-26 더 존스 홉킨스 유니버시티 인지능 손상의 치료를 위한 표적

Also Published As

Publication number Publication date
EP1611238A4 (en) 2007-07-04
CA2516619A1 (en) 2004-09-10
WO2004076675A3 (en) 2005-03-17
KR20050115245A (ko) 2005-12-07
WO2004076675A2 (en) 2004-09-10
JP2006524637A (ja) 2006-11-02
US20060121488A1 (en) 2006-06-08
MXPA05009134A (es) 2005-12-05
DE602004021574D1 (de) 2009-07-30
DK1611238T3 (da) 2009-10-26
EP1611238B1 (en) 2009-06-17
ES2328811T3 (es) 2009-11-18
ATE433993T1 (de) 2009-07-15
EP1611238A2 (en) 2006-01-04
AU2004214938A1 (en) 2004-09-10
AU2004214938B2 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
EP1611238A4 (en) MODULATORY CONNECTIONS AND METHOD FOR GLUTAMAT TRANSPORT
WO2020102741A8 (en) Methods and compositions for protein sequencing
ATE486087T1 (de) Fgf-5-bindende und geträgerte peptide
BRPI0713421A2 (pt) Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
IL191374A0 (en) Methods for the treatment of muscle loss
WO2003103718A3 (en) INTRACELLULAR ADMINISTRATION OF BIOLOGICAL EFFECTORS
GB9911047D0 (en) Assay method and means
ES2507094T3 (es) Proteína específica del timo
EA200700136A1 (ru) Анти-cd154-антитела
WO2003089456A3 (en) Peptide inhibitors of protein kinase c
WO2007087131A3 (en) Peptide prodrugs
EA201490735A1 (ru) Лечение дегенеративного заболевания сустава
WO2007053390A3 (en) Methods for the use of branched chain amino acids
MY151330A (en) Systems and method for separating proteins from connective tissue
WO2003011898A3 (fr) Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
MXPA03000316A (es) Reactivos y metodos para la identificacion de agentes de enlace.
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
MXPA05006034A (es) Proteina de duplicacion.
DK1117682T3 (da) Chi-conotoksin-peptider som inhibitorer af neuronale amintransportere
ATE405827T1 (de) Screening-verfahren
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
AR128224A1 (es) Compuestos y métodos para tratar la ataxia de friedreich
WO2004042035A3 (en) Organic anion transport polypeptide related protein-4 (oatprp4) gene in tourette syndrome and related disorders
WO2004018700A3 (en) Method of modulating and of identifying agents that modulate intracellular calcium

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)